All stock lists
Addex Therapeutics Ltd. (NASDAQ:ADXN)
CH · Delayed Price · Currency is USD
Healthcare · Biotechnology
3.01+0.04 (+1.35%)
Insider Score
––Not scored
ADXN Insider Score
Insiders here have filed 7 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
ADXN Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 9.91 K | 7.69 K | 248.00 | 29.72 K | 36.38 K | 0.00 |
| Revenue Growth (YoY) | -72.76 % | — | -83.55 % | -44.79 % | -68.45 % | -100.00 % |
| Cost of Revenue | 25.13 K | 36.13 K | 0.00 | 0.00 | 234.45 K | 0.00 |
| Gross Profit | -15.22 K | -28.44 K | 248.00 | 29.72 K | -198.08 K | 0.00 |
| SG&A Expense | 614.58 K | 389.31 K | 567.98 K | 459.92 K | 411.96 K | 448.07 K |
| R&D Expense | 37.85 K | 9.39 K | 3.86 K | 85.26 K | 68.49 K | 32.58 K |
| Operating Expenses | 627.60 K | 451.39 K | 779.51 K | 725.90 K | 534.82 K | 606.26 K |
| Operating Income | -642.47 K | -479.83 K | -779.26 K | -696.17 K | -732.90 K | -606.26 K |
| Pretax Income | -1.74 M | -1.71 M | -1.83 M | -1.58 M | -1.96 M | -1.47 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -1.74 M | -1.71 M | -1.84 M | -1.58 M | -1.84 M | -1.47 M |
| EPS (Basic) | -1.20 | -1.20 | -1.54 | -1.67 | -2.56 | -1.80 |
| EPS (Diluted) | -1.20 | -1.20 | -1.54 | -1.67 | -2.40 | -1.80 |
| Shares Outstanding | 1.45 M | 1.43 M | 1.19 M | 938.98 K | 721.04 K | 819.54 K |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.